Warning: The NCBI web site requires JavaScript to function. more...
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.
Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP.
Filaria J. 2003 Oct 24;2 Suppl 1:S4.
Related citations
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Ducorps M, Gardon-Wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, Chippaux JP.
Bull Soc Pathol Exot. 1995;88(3):105-12. French.
Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.
Lancet. 1997 Jul 5;350(9070):18-22.
Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.
Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP.
Am J Trop Med Hyg. 1998 Apr;58(4):461-9.
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.
Twum-Danso NA.
Filaria J. 2003 Oct 24;2 Suppl 1:S7.
Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.
Wanji S, Tendongfor N, Esum M, Yundze SS, Taylor MJ, Enyong P.
Filaria J. 2005 Apr 7;4(1):2.
Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.
Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M.
Am J Trop Med Hyg. 2009 Dec;81(6):1056-61.
Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon.
Boussinesq M, Gardon J, Kamgno J, Pion SD, Gardon-Wendel N, Chippaux JP.
Ann Trop Med Parasitol. 2001 Jul;95(5):495-507.
Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas.
Filaria J. 2003 Oct 24;2 Suppl 1:S2.
Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg).
Kamgno J, Pion SD, Tejiokem MC, Twum-Danso NA, Thylefors B, Boussinesq M.
Trans R Soc Trop Med Hyg. 2007 Aug;101(8):777-85. Epub 2007 May 24.
Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control.
Thomson MC, Obsomer V, Kamgno J, Gardon J, Wanji S, Takougang I, Enyong P, Remme JH, Molyneux DH, Boussinesq M.
Filaria J. 2004 Aug 6;3(1):7.
[Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose].
Kamgno J, Gardon J, Boussinesq M.
Med Trop (Mars). 2000;60(3):275-7. French.
Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.
Twum-Danso NA, Meredith SE.
Trop Med Int Health. 2003 Sep;8(9):820-31.
Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting?
Pion SD, Clarke P, Filipe JA, Kamgno J, Gardon J, Basáñez MG, Boussinesq M.
Parasitology. 2006 Jun;132(Pt 6):843-54. Epub 2006 Feb 10.
Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.
Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG.
Am J Trop Med Hyg. 2010 Jul;83(1):28-32.
Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia.
Fobi G, Gardon J, Santiago M, Ngangue D, Gardon-Wendel N, Boussinesq M.
Ophthalmic Epidemiol. 2000 Mar;7(1):27-39.
Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the progr,ammes of Community-Directed Treatment with Ivermectin carried out in Africa.
Pion DS, Gardon J, Kamgno J, Gardon-Wendel N, Chippaux JP, Boussinesq M.
Parasitology. 2004 Nov;129(Pt 5):613-26.
Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia.
Tsague-Dongmo L, Kamgno J, Pion SD, Moyou-Somo R, Boussinesq M.
Ann Trop Med Parasitol. 2002 Oct;96(7):707-15.
Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
Mackenzie CD, Geary TG, Gerlach JA.
Filaria J. 2003 Oct 24;2 Suppl 1:S5.
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.
Filaria J. 2003 Oct 24;2 Suppl 1:S3.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on